ENTRY       D02096                      Drug
NAME        Fosphenytoin sodium (USP);
            Cerebyx (TN);
            Sesquient (TN)
PRODUCT     CEREBYX (Pfizer Laboratories Div Pfizer)
            CEREBYX (Pfizer Laboratories Div Pfizer)
  GENERIC   FOSPHENYTOIN (Fresenius Kabi USA)
            FOSPHENYTOIN SODIUM (Amneal Pharmaceuticals LLC)
            FOSPHENYTOIN SODIUM (Amneal Pharmaceuticals LLC)
            FOSPHENYTOIN SODIUM (Hikma Pharmaceuticals USA)
            FOSPHENYTOIN SODIUM (West-Ward Pharmaceuticals Corp)
            FOSPHENYTOIN SODIUM (Wockhardt USA LLC.)
FORMULA     C16H13N2O6P. 2Na
EXACT_MASS  406.0307
MOL_WEIGHT  406.2375
CLASS       Neuropsychiatric agent
             DG03199  Antiepileptic agent
              DG02031  Hydantoin antiepileptic
            Metabolizing enzyme substrate
             DG01642  CYP2C9 substrate
             DG01639  CYP2C19 substrate
            Metabolizing enzyme inducer
             DG02891  CYP2B6 inducer
             DG02853  CYP3A/CYP3A4 inducer
              DG01635  CYP3A4 inducer
            Transporter inducer
             DG01893  ABCB1 inducer
REMARK      ATC code: N03AB05
            Chemical structure group: DG00847
            Product (DG00847): D02096<US> D07595<JP>
EFFICACY    Anticonvulsant
COMMENT     Hydantoin derivative
            Active form of prodrug: Phenytoin [DR:D00512]
TARGET      SCN1A [HSA:6323] [KO:K04833]
            SCN2A [HSA:6326] [KO:K04834]
            SCN3A [HSA:6328] [KO:K04836]
            SCN4A [HSA:6329] [KO:K04837]
            SCN5A [HSA:6331] [KO:K04838]
            SCN8A [HSA:6334] [KO:K04840]
            SCN9A [HSA:6335] [KO:K04841]
            SCN10A [HSA:6336] [KO:K04842]
            SCN11A [HSA:11280] [KO:K04843]
  PATHWAY   hsa04728(6323)  Dopaminergic synapse
METABOLISM  Enzyme: CYP2C9 [HSA:1559]; CYP2C19 [HSA:1557]
INTERACTION CYP induction: CYP3A4 [HSA:1576], CYP2B6 [HSA:1555]
            Transporter induction: ABCB1 [HSA:5243]
STR_MAP     map07033  Anticonvulsants
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             N NERVOUS SYSTEM
              N03 ANTIEPILEPTICS
               N03A ANTIEPILEPTICS
                N03AB Hydantoin derivatives
                 N03AB05 Fosphenytoin
                  D02096  Fosphenytoin sodium (USP) &lt;US&gt;
            USP drug classification [BR:br08302]
             Anticonvulsants
              Sodium Channel Agents
               Fosphenytoin
                D02096  Fosphenytoin sodium (USP)
            Drug groups [BR:br08330]
             Neuropsychiatric agent
              DG03199  Antiepileptic agent
               DG02031  Hydantoin antiepileptic
                DG00847  Fosphenytoin
                 D02096  Fosphenytoin sodium
             Metabolizing enzyme substrate
              DG01642  CYP2C9 substrate
               DG00847  Fosphenytoin
                D02096  Fosphenytoin sodium
              DG01639  CYP2C19 substrate
               DG00847  Fosphenytoin
                D02096  Fosphenytoin sodium
             Metabolizing enzyme inducer
              DG02891  CYP2B6 inducer
               DG00847  Fosphenytoin
                D02096  Fosphenytoin sodium
              DG02853  CYP3A/CYP3A4 inducer
               DG01635  CYP3A4 inducer
                DG00847  Fosphenytoin
                 D02096  Fosphenytoin sodium
             Transporter inducer
              DG01893  ABCB1 inducer
               DG00847  Fosphenytoin
                D02096  Fosphenytoin sodium
            Drug classes [BR:br08332]
             Neuropsychiatric agent
              DG03199  Antiepileptic agent
               D02096  Fosphenytoin sodium
            Target-based classification of drugs [BR:br08310]
             Ion channels
              Voltage-gated ion channels
               Sodium channels
                SCN1A
                 D02096  Fosphenytoin sodium (USP) &lt;US&gt;
                SCN2A
                 D02096  Fosphenytoin sodium (USP) &lt;US&gt;
                SCN3A
                 D02096  Fosphenytoin sodium (USP) &lt;US&gt;
                SCN4A
                 D02096  Fosphenytoin sodium (USP) &lt;US&gt;
                SCN5A
                 D02096  Fosphenytoin sodium (USP) &lt;US&gt;
                SCN8A
                 D02096  Fosphenytoin sodium (USP) &lt;US&gt;
                SCN9A
                 D02096  Fosphenytoin sodium (USP) &lt;US&gt;
                SCN10A
                 D02096  Fosphenytoin sodium (USP) &lt;US&gt;
                SCN11A
                 D02096  Fosphenytoin sodium (USP) &lt;US&gt;
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D02096
             Drug transporters
              D02096
            Pharmacogenomic biomarkers [br08341.html]
             Polymorphisms and mutations affecting drug response
              D02096
            Drug groups [BR:br08330]
             Neuropsychiatric agent
              DG03199  Antiepileptic agent
               DG02031  Hydantoin antiepileptic
                DG00847  Fosphenytoin
             Metabolizing enzyme substrate
              DG01642  CYP2C9 substrate
               DG00847  Fosphenytoin
              DG01639  CYP2C19 substrate
               DG00847  Fosphenytoin
             Metabolizing enzyme inducer
              DG02891  CYP2B6 inducer
               DG00847  Fosphenytoin
              DG02853  CYP3A/CYP3A4 inducer
               DG01635  CYP3A4 inducer
                DG00847  Fosphenytoin
             Transporter inducer
              DG01893  ABCB1 inducer
               DG00847  Fosphenytoin
            Prodrugs [br08324.html(DG00847)]
             DG00847
DBLINKS     CAS: 92134-98-0
            PubChem: 7849157
            LigandBox: D02096
            NIKKAJI: J353.480D
ATOM        27
            1   Z   Na   13.2864  -17.8245 #+
            2   Z   Na    9.8618  -21.7310 #+
            3   C1z C    17.0800  -21.2800
            4   N1x N    17.5700  -20.0200
            5   C5x C    16.4500  -19.2500
            6   N1y N    15.2600  -20.0200
            7   C5x C    15.7500  -21.2800
            8   O5x O    16.4500  -17.7800
            9   O5x O    14.9800  -22.4700
            10  C8y C    18.4800  -21.2800
            11  C8x C    19.1800  -22.5400
            12  C8x C    20.6500  -22.5400
            13  C8x C    21.3500  -21.3500
            14  C8x C    20.5800  -20.0900
            15  C8x C    19.1800  -20.0900
            16  C8y C    17.0800  -22.7500
            17  C8x C    15.8900  -23.3800
            18  C8x C    15.8900  -24.7800
            19  C8x C    17.1500  -25.5500
            20  C8x C    18.3400  -24.8500
            21  C8x C    18.3400  -23.4500
            22  C1b C    14.1400  -19.3200
            23  O2b O    12.9500  -20.0200
            24  P1b P    11.7600  -19.3200
            25  O1c O    10.4300  -20.1600 #-
            26  O1c O    11.7600  -17.9200 #-
            27  O1c O    10.5700  -18.6200
BOND        27
            1     3   4 1
            2     4   5 1
            3     5   6 1
            4     6   7 1
            5     3   7 1
            6     5   8 2
            7     7   9 2
            8     3  10 1
            9    10  11 2
            10   11  12 1
            11   12  13 2
            12   13  14 1
            13   14  15 2
            14   10  15 1
            15    3  16 1
            16   16  17 2
            17   17  18 1
            18   18  19 2
            19   19  20 1
            20   20  21 2
            21   16  21 1
            22   22   6 1
            23   22  23 1
            24   23  24 1
            25   24  25 1
            26   24  26 1
            27   24  27 2
///
